EQUITIES

Robust. Fundamental. Dynamic.

Our teams exercise independent thought with high conviction, resulting in portfolios that we believe are well positioned to address our clients' challenges – all within robust risk control frameworks.

vd-icon_Currency_CashUSD

$243.6bn
Equities Assets Under Management

vd-icon_People_3_Group v3

148
Equities Investment
Professionals

vd-icon_Bulleye_Target v3

19
Average Years’ Financial
Industry Experience

As at 30 June 2025

<span class="notranslate">no data</span>

$243.6bn
Equities Assets Under Management

148
Equities Investment
Professionals

19
Average Years’ Financial
Industry Experience

As at 30 June 2025

We measure success by a single factor: client outcomes. As a pure asset manager, our sole mission is to deliver consistent long-term risk-adjusted returns that exceed our benchmarks and peers, regardless of the prevailing investment landscape.

Featured strategies

Global Life Sciences

By understanding the science and business of health care, our experienced team seeks to invest in companies addressing unmet medical needs or improving efficiencies.

Biotechnology Innovation

A biotechnology strategy that seeks to leverage a disciplined approach to identify compelling opportunities across the biotech landscape in both public and private investments

Global Technology Leaders

A global approach to investing in technology companies from a highly experienced team

Insights

Chart to Watch: Companies learn quick lessons on navigating tariffs

U.S. companies have thus far withstood the Trump administration’s barrage of tariffs, but signs of stress are emerging in the most exposed sectors.

Quick View: Will Iron Lady Takaichi be the catalyst needed to drive Japanese stocks?

Key considerations for Japanese equity investors following the election of new LDP head, Sanae Takaichi.

Chart to Watch: An opening to increase tech exposure?

Tech sector volatility can lead to attractive entry points for investors seeking to increase exposure to powerful secular themes.